Patients with osteoarthritis pain will soon have a new generic drug.
The Food and Drug Administration has given Lupin the green light for meloxicam capsules in dosage strengths of 5 mg and 10 mg.
The product is the generic of Zyla Life Sciences’ Vivlodex capsules, 5 mg and 10 mg.
It will be manufactured at Lupin’s Aurangabad facility in India. Lupin said that it expects to launch the product shortly.
Meloxicam had a market value of approximately $14 million, according to IQVIA data from March.